DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival.
DNA methylation
glioblastoma
immune infiltration
tumor microenvironment
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
25 02 2021
25 02 2021
Historique:
pubmed:
2
11
2020
medline:
28
4
2021
entrez:
1
11
2020
Statut:
ppublish
Résumé
Histologically classified glioblastomas (GBM) can have different clinical behavior and response to therapy, for which molecular subclassifications have been proposed. We evaluated the relationship of epigenetic GBM subgroups with immune cell infiltrations, systemic immune changes during radiochemotherapy, and clinical outcome. 450K genome-wide DNA methylation was assessed on tumor tissue from 93 patients with newly diagnosed GBM, treated with standard radiochemotherapy and experimental immunotherapy. Tumor infiltration of T cells, myeloid cells, and Programmed cell death protein 1 (PD-1) expression were evaluated. Circulating immune cell populations and selected cytokines were assessed on blood samples taken before and after radiochemotherapy. Forty-two tumors had a mesenchymal, 27 a receptor tyrosine kinase (RTK) II, 17 RTK I, and 7 an isocitrate dehydrogenase (IDH) DNA methylation pattern. Mesenchymal tumors had the highest amount of tumor-infiltrating CD3+ and CD8+ T cells and IDH tumors the lowest. There were no significant differences for CD68+ cells, FoxP3+ cells, and PD-1 expression between groups. Systemically, there was a relative increase of CD8+ T cells and CD8+ PD-1 expression and a relative decrease of CD4+ T cells after radiochemotherapy in all subgroups except IDH tumors. Overall survival was the longest in the IDH group (median 36 mo), intermediate in RTK II tumors (27 mo), and significantly lower in mesenchymal and RTK I groups (15.5 and 16 mo, respectively). Methylation based stratification of GBM is related to T-cell infiltration and survival, with IDH and mesenchymal tumors representing both ends of a spectrum. DNA methylation profiles could be useful in stratifying patients for immunotherapy trials.
Sections du résumé
BACKGROUND
Histologically classified glioblastomas (GBM) can have different clinical behavior and response to therapy, for which molecular subclassifications have been proposed. We evaluated the relationship of epigenetic GBM subgroups with immune cell infiltrations, systemic immune changes during radiochemotherapy, and clinical outcome.
METHODS
450K genome-wide DNA methylation was assessed on tumor tissue from 93 patients with newly diagnosed GBM, treated with standard radiochemotherapy and experimental immunotherapy. Tumor infiltration of T cells, myeloid cells, and Programmed cell death protein 1 (PD-1) expression were evaluated. Circulating immune cell populations and selected cytokines were assessed on blood samples taken before and after radiochemotherapy.
RESULTS
Forty-two tumors had a mesenchymal, 27 a receptor tyrosine kinase (RTK) II, 17 RTK I, and 7 an isocitrate dehydrogenase (IDH) DNA methylation pattern. Mesenchymal tumors had the highest amount of tumor-infiltrating CD3+ and CD8+ T cells and IDH tumors the lowest. There were no significant differences for CD68+ cells, FoxP3+ cells, and PD-1 expression between groups. Systemically, there was a relative increase of CD8+ T cells and CD8+ PD-1 expression and a relative decrease of CD4+ T cells after radiochemotherapy in all subgroups except IDH tumors. Overall survival was the longest in the IDH group (median 36 mo), intermediate in RTK II tumors (27 mo), and significantly lower in mesenchymal and RTK I groups (15.5 and 16 mo, respectively).
CONCLUSIONS
Methylation based stratification of GBM is related to T-cell infiltration and survival, with IDH and mesenchymal tumors representing both ends of a spectrum. DNA methylation profiles could be useful in stratifying patients for immunotherapy trials.
Identifiants
pubmed: 33130898
pii: 5948531
doi: 10.1093/neuonc/noaa247
pmc: PMC7906065
doi:
Substances chimiques
Isocitrate Dehydrogenase
EC 1.1.1.41
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
240-250Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Acta Neuropathol. 2018 Aug;136(2):181-210
pubmed: 29967940
Nat Immunol. 2011 Jun;12(6):492-9
pubmed: 21739672
J Neuroimmunol. 2013 Nov 15;264(1-2):71-83
pubmed: 24045166
Clin Cancer Res. 2011 Mar 15;17(6):1603-15
pubmed: 21135147
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
Int J Cancer. 2017 Nov 1;141(9):1891-1900
pubmed: 28681455
Acta Neuropathol. 1989;78(2):189-93
pubmed: 2750489
Cancer Immunol Immunother. 2015 Apr;64(4):419-27
pubmed: 25555571
J Neurosurg. 1978 Dec;49(6):854-61
pubmed: 731302
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
J Neurooncol. 2013 Oct;115(1):9-17
pubmed: 23824536
Neuro Oncol. 2016 Oct;18(10):1357-66
pubmed: 27370400
Oncoimmunology. 2019 Aug 22;8(11):e1655360
pubmed: 31646100
Clin Cancer Res. 2011 Jul 1;17(13):4296-308
pubmed: 21478334
J Clin Neurosci. 2010 Nov;17(11):1381-5
pubmed: 20727764
Nat Rev Cancer. 2014 Feb;14(2):92-107
pubmed: 24457416
Clin Cancer Res. 2014 Nov 15;20(22):5620-9
pubmed: 25398845
Surg Neurol. 1985 Mar;23(3):221-6
pubmed: 2983448
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
Tumori. 1979 Feb 28;65(1):119-25
pubmed: 220763
Neuro Oncol. 2011 Apr;13(4):393-400
pubmed: 21339188
Neurosurgery. 2006 Nov;59(5):988-99; discussioin 999-1000
pubmed: 17143233
Cancer Cell. 2012 Oct 16;22(4):425-37
pubmed: 23079654
Nature. 2018 Mar 22;555(7697):469-474
pubmed: 29539639
J Mol Diagn. 2016 May;18(3):350-361
pubmed: 26927331
J Neurooncol. 2010 Sep;99(2):261-72
pubmed: 20146084
Clin Neuropathol. 1984 Jul-Aug;3(4):143-7
pubmed: 6478676
Clin Cancer Res. 2013 Sep 15;19(18):4951-60
pubmed: 23864165
Cancer Cell. 2006 Mar;9(3):157-73
pubmed: 16530701
Clin Cancer Res. 2011 Aug 15;17(16):5473-80
pubmed: 21737504
N Engl J Med. 2009 Feb 19;360(8):765-73
pubmed: 19228619
Neuro Oncol. 2015 Oct;17 Suppl 4:iv1-iv62
pubmed: 26511214
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Epigenetics. 2013 Feb;8(2):203-9
pubmed: 23314698
Ann Neurol. 1978 Sep;4(3):219-24
pubmed: 718133
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Neuro Oncol. 2017 Oct 19;19(11):1460-1468
pubmed: 28531337